Biotech China 2014

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2010 Flare Consensus Initiative: International Consensus to Define Disease Flare in Lupus Lupus 2010; in press
2. 2010 Interstitial Lung Disease with Connective Tissue Diseases Current Rheumatology Reviews 2010; 6:88-90
3. 2010 OMERACT How to get into the “Act”. The Rheumatologist 2010; 4:1, 24-5
4. 2010 A first step to assess harm and benefit in clinical trials in one scale J Clin Epi 2010; 63:627-32
5. 2010 Elevated liver enzyme tests among rheumatoid arthritis and psoriatic arthritis patients treated with methotrexate and/or leflunomide Ann Rheum Dis 2010; 69:43-7.
6. 2010 Systemic Lupus Erythematosus-Related Interstitial Lung Disease Current Rheumatology Reviews 2010; 6:99-107.
7. 2010 Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol Rheumatology 2010; 10.1093/rheumatology/keq109
8. 2010 Contributions of Change in Clinical Status Parameters to Patient Global Impression of Change (PGIC) Scores Among Persons with Fibromyalgia Treated With Milnacipran or Placebo Pain 2010; 149:373-8
9. 2010 Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension. Results of a systematic literature analysis by the EPOSS group J Rheumatol 2010; 37:105-15.
10. 2010 Flare” and Disease Worsening in Rheumatoid Arthritis: Time for a Definition Int J Rheum 2009; in press
11. 2010 Risk of Elevated Liver Enzymes Associated with TNF Inhibitor Utilization in Patients with Rheumatoid Arthritis Ann Rheum Ds 2010; 69:1612-17
12. 2010 Newer Biologic Agents Improve Health Related Quality of Life and Productivity in Rheumatoid Arthritis Drugs 2010; 70:121-145
13. 2009 Variation in Outcome Measures in Hip and Knee Arthroplasty Clinical Trials: A Proposed Approach to Achieving Consensus J Rheumatol 2009; 36:2050-6
14. 2009 International Consensus Conference on outcome measures in rheumatology clinical trials J Rheumatol 2009; 36:1765-8.
15. 2009 Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy:  the FAST4WARD study Ann Rheum Dis 2009; 68:805-11
16. 2009 Efficacy and Safety of Certolizumab Pegol Plus Methotrexate in Active Rheumatoid Arthritis: The RAPID 2 Study. A randomized controlled trial Ann Rheum Dis 2009; 68:797-804
17. 2009 Evaluation of Composite Measures of Treatment Response Without Acute Phase Reactants in Patients with Rheumatoid Arthritis Rheumatology 2009: 48:686-90
18. 2009 Measuring worker productivity: frameworks & measures J Rheumatol 2009: 36:2100–9
19. 2009 Novel Evidence-Based Systemic Lupus Erythematosus Responder Index Arth Rheum 2009; 61:1143-51
20. 2009 Health-related quality-of-life measures and analyses in rheumatic diseases Contemp Topics Rheum Arthritis.2009; 3:5-10.
21. 2009 Rheumatoid Arthritis: Next-Generation Biologic Therapies [Medscape]. http://cme.medscape.com/viewarticle/704075.   
22. 2009 Spondyloarthritis is associated with poor function and physical health related quality of life J Rheumatol 2009; 36:1012-1020
23. 2009 Health care utilization in patients with spondyloarthropathies Rheumatology 2009; 48:272-6
24. 2009 Randomized Controlled Trial Design in Rheumatoid Arthritis – The Past Decade Arth Research Therapy 2009; 11: 205-15.
25. 2009 The Impact of Rheumatoid Arthritis and Treatment on Patients’ Lives Clin Exp Rheum 2009; in press.
26. 2009 Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: a randomized controlled trial Arth Res Ther 2009; 11:R170.
27. 2009 Viewpoint: Use of “Spydergrams” to present and interpret Health related quality of life data across rheumatic diseases Ann Rheum Ds 2009; 68:1800-04
28. 2009 Effect of certolizumab pegol with methotrexate on home and workplace productivity and social activities in patients with active rheumatoid arthritis Arth Rheum 2009; 61:1592-600
29. 2009 Fibromyalgia Syndrome Module at OMERACT 9 J Rheumatol 2009; 36:2318-29
30. 2009 Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome J Rheumatol 2009; 36:2330-4
31. 2009 Measures of Response in Clinical Trials of Systemic Sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in PAH Related to Systemic Sclerosis (EPOSS). J Rheumatol 2009; 36:2356-61
32. 2009 The OMERACT-ICF Reference Group: Integrating the ICF into the OMERACT process: Opportunities and challenges J Rheumatol 2009; 36:2057-60
33. 2009 Developing a Standardized Definition of Disease “Flare” in Rheumatoid Arthritis (OMERACT 9 Special Interest Group J Rheumatol 2009; 36:2335-41
34. 2009 How to Ascertain Drug Safety in the Context of Benefit. Controversies and Concerns J Rheumatol 2009; 36:2114-21
35. 2009 Observations of the OMERACT Drug Safety Summit, May 2008 J Rheumatol 2009; 36:2110-13
36. 2008 Treatment-Related Improvement in Physical Function Varies with Duration of Rheumatoid Arthritis; A Pooled Analysis of Clinical Trial Results Ann Rheum Dis 2008; 67:238-243
37. 2008 Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations Ann Rheum Dis 2008; 67:1360-4
38. 2008 Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations Arth Rheum 2008; 59:1371-7
39. 2008 Certolizumab Pegol Plus Methotrexate Is Significantly More Effective Than Placebo Plus Methotrexate in Active Rheumatoid Arthritis: The RAPID 1 Study Arth Rheum 2008; 58:3319-29
40. 2008 An Update to ‘Take Two and Call Me in the Morning.’ The Rheumatology Report; Summer 2008: 9-10
41. 2008 Effects of Prasterone on Bone Mineral Density in Women with Active Systemic Lupus Erythematosus Receiving Chronic Glucocorticoid Therapy J Rheumatol 2008; 35:1567-75
42. 2008 Gout is associated with more comorbidities, poorer Health Related Quality of Life and higher health care utilization in US Veterans Ann Rheum Dis 2008; 67:1310-6
43. 2008 TNF Antagonist Responsiveness in a United States Rheumatoid Arthritis Cohort Am J Med 2008; 121:532-8
44. 2008 A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic Gout Ann Rheum Dis 2008; 67: 888-91.
45. 2008 Improved Health-Related Quality of Life with Effective Disease-Modifying Antirheumatic Drugs: Evidence from Randomized Controlled Trials Am J Managed Care 2008; 14:234-54
46. 2007 Biologic therapies in rheumatology: lessons learned, future directions Nature Reviews Drug Discovery 2007; 6:75-92.
47. 2007 Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema J Rheumatol 2007; 34:607-15
48. 2007 Clinical Evidence for Utilization of the A3 Adenosine Receptor as a Target to Treat Rheumatoid Arthritis: Data from a Phase II Clinical Trial J Rheumatol 2007; 34: 41-8
49. 2007 Editorial: Long Term Treatment Benefits are Best Reflected in Patient Reported Outcomes J Rheumatol 2007; 34: 2317-9
50. 2007 A novel means to demonstrate early efficacy of a product in Systemic Lupus Erythematosus Current Rheum Reports 2007; 9: 27-30.
51. 2007 In Patients with Cardiovascular Risk Receiving Low Dose Aspirin, is a COX-2 Selective Agent Preferable to nsNSAIDs for Antiinflammatory Therapy? Lancet 2007; 370: 2138-57
52. 2007 Outcome measures in rheumatoid arthritis: the OMERACT process Expert Reviews Clin Immun 2007; 3:271-5.
53. 2007 Interleukin-6 Inhibition: Tolerability profile and clinical implications. Bulletin of NYU Hospital for Joint Diseases 2007; 65:S21-4
54. 2007 Rheumatoid Arthritis Consult Collection. Selective T-cell costimulation modulation: A new approach to treating rheumatoid arthritis Am J Orthop 2007; 8: 8-14
55. 2007 OMERACT: An international initiative to improve outcome measurement in rheumatology Trials 2007: 8:38 
56. 2007 Worker Productivity Outcome Measures in Arthritis J Rheumatol 2007; 34:1372-80
57. 2007 Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of quantitative hierarchical levels of evidence schema J Rheumatol 2007; 34:607-615
58. 2007 Systemic Sclerosis – Continuing progress in developing clinical measures of response J Rheumatol 2007; 34:1194-1200
59. 2007 Consensus on a core set domains for psoriatic arthritis J Rheumatol 2007; 34:1167-70
60. 2007 Outcome measures in psoriatic arthritis J Rheumatol 2007; 34:1159-1166.
61. 2007 Computer based methods for measurement of joint space width: update of an ongoing OMERACT project. J Rheumatol 2007; 34:874-883
62. 2007 Health-related quality of life in patients with systemic lupus erythematosus: an update Ann Acad Med Singapore 2007; 36:115-122
63. 2007 OMERACT 8 – 8th international consensus conference on outcome measures in rheumatology clinical trials J Rheumatol 2007; 34:599
64. 2007 Lessons learned from clinical trials in SLE Autoimmunity Reviews 2007; 6:209-214
65. 2006 Are American College of Rheumatology 50% Response Criteria (ACR 50) Superior to 20% Criteria (ACR20) to Distinguish Active from Comparator Treatment in Rheumatoid Arthritis Clinical Trials Reported Since 1997? A Metaanalysis of Discriminant Capacities Ann Rheum Ds 2006; 65:1602–7
66. 2006 Leflunomide in juvenile idiopathic arthritis Future Rheumatol 2006; 1:673-682.
67. 2006 Risedronate Decreases Biochemical Markers of Cartilage Degradation but Does Not Decrease Symptoms or Slow X-Ray Progression in Patients with Medical Compartment Osteoarthritis of the Knee: Result of the Two-Year Multinational Knee OA Structural Arthritis (KOSTAR) Study Arth Rheum 2006; 54:3494-3507
68. 2006 Sustained benefit in Rheumatoid Arthritis following one course of rituximab: improvements in physical function over 2 years Rheumatology 2006; 45:1505-1513.
69. 2006 Monitoring disease activity of rheumatoid arthritis in clinical practice: contributions from clinical trials Nature Clin Prac Rheum 2006; 2:611-18
70. 2006 Cardiovascular Effect of Selective COX-2 Inhibition: Is There a Class Effect? The International COX-2 Study Group J Rheumatol 2006; 33:1403-8.
71. 2006 An integrated analysis of 5 double blind randomized controlled trials of the safety and efficacy of a hyaluronan product for intra-articular injection in osteoarthritis of the knee. Osteoarthritis Cart 2006; 14:859-66
72. 2006 Expectations from patients with rheumatoid arthritis regarding COX-2s – cutting to the heart of the matter J Cardiovasc Pharm 2006; 47: S55-9
73. 2006 Measuring quality in arthritis care; the Arthritis Foundation’s Quality Indicator Set for rheumatoid arthritis Semin Arth Rheum 2006; 35:205-7
74. 2006 Patient reported pain is central to OMERACT rheumatology core measurement sets. DIA Journal 2006; 40:111-116
75. 2005 Leflunomide improves physical function and health-related quality of life when added to methotrexate in patients with active rheumatoid arthritis J Clin Rheum 2005; 32:590-601
76. 2005 Expert Panel report use of combination of leflunomide with biological agents in treatment of RA. J Rheumatol 2005; 32:1620-31
77. 2005 Fibromyalgia Syndrome J Rheumatol. 2005; 32:2270-7
78. 2005 Outcome Measures in Psoriatic Arthritis J Rheumatol. 2005; 32: 2262-9.
79. 2005 Measurement of joint space width and erosion size J Rheumatol. 2005; 32: 2456-61
80. 2005 Minimal disease activity for rheumatoid arthritis: a preliminary definition J Rheumatol 2005; 32:2016-24.
81. 2005 Omeract 7 – 7th International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials J Rheumatol 2005; 32: 2014-5.
82. 2005 Improvement in Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus following Sustained Reductions in Anti-dsDNA Antibodies Expert Review Pharmacoeconomics & Outcomes Research 2005: 5:317-26
83. 2005 Relationship between anti dsDNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arth Rheum 2005; 52: 1129-37
84. 2005 Physical Function and Health-Related Quality of Life: Analysis of 2-Year Data from Randomized, Controlled Studies of Leflunomide, Sulfasalazine, or Methotrexate in Patients with Active Rheumatoid Arthritis J Rheumatol 2005; 32: 590-601.
85. 2005 Pharmacovigilance in the Treatment of Rheumatoid Arthritis J Rheumatol 2005; 32: in press
86. 2005 Long-term Open-label Study of Preliminary Safety and Efficacy of Leflunomide in Polyarticular Course Juvenile Rheumatoid Arthritis (JRA) Arth Rheum 2005: 52: 554-562
87. 2005 Expanding the Definition of Clinical Differences: From Minimally Clinically Important Differences (MCID) to Really Important Differences (RID). Analyses in 8,931 Patients with Rheumatoid Arthritis J Rheumatol 2005; 32: 583-9.
88. 2005 Leflunomide or Methotrexate for the Treatment of Juvenile Rheumatoid Arthritis NEJM 2005: 352:1655-66
89. 2004 Patient versus Physician-Reported Outcomes in Rheumatoid Arthritis Patients Treated with Recombinant Interleukin-1 Receptor Antagonist (Anakinra) Therapy Rheumatology 2004: 43: 648-95
90. 2004 Outcome Measures in Randomized Controlled Trials in Osteoarthritis Curr Rheumatol Reports 2004; 6:20-30
91. 2004 Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage. 2004; 12:389-99
92. 2004 Concise Communication: Counterpoint: From the Trenches; A Commentary on “Add-on or step-up trials for new drug development in rheumatoid arthritis: a new standard? Arth Rheum 2004: 50:1344-8. 648-56.
93. 2004 Long-term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years: concise report Ann Rheum Ds 2004: 63:737-9
94. 2004 Variability of precision in scoring radiographic abnormalities in RA J Rheumatol 2004: 31:1062-72
95. 2004 Patient reported outcomes better discriminate active treatment from placebo in RA clinical trials. Rheumatology 2004: 43:640-7
96. 2004 Efficacy and Safety of Leflunomide 10 mg vs 20 mg once daily in patients with active RA: A multinational double blind randomized trial Rheumatology 2004: 43:744-9
97. 2004 Lessons Learned and Future Directions Lupus 2004; 13:406-411
98. 2004 The role of Interleukin-1 in bone resorption in rheumatoid arthritis Rheumatology 2004; 43: i10-16
99. 2004 The efficacy of leflunomomide monotherapy in rheumatoid arthritis: towards the goal of disease modifying antirheumatic drug therapy J Rheumatol 2004; 31: S13-20
100. 2004 Leflunomide: A manageable safety profile J Rheumatol 2004: 31:S21-24.
101. 2004 Leflunomide in combination therapy J Rheumatol 2004; 31:S24-30
102. 2004 Effects of the cyclooxygenase 2 specific inhibitor valdecoxib versus NSAIDs and placebo on cardiovascular thrombotic events in patients with arthritis Am J Therapeutics 2004; 11:244-250
103. 2004 Benefits vs Risks of TNF inhibitors New Developments in Rheumatic Diseases 2004; 2: 1-8
104. 2004 Longer Term Benefits of Treating Rheumatoid Arthritis: Assessment of Radiographic Damage and Physical Function over 2 years in Clinical Trials Clin Exp Rheum. 2004: 22: S57-64
105. 2004 Combination leflunomide and methotrexate therapy for patients with active rheumatoid arthritis failing methotrexate monotherapy: an open-label extension of a randomized, double-blind, placebo-controlled trial J Rheumatol 2004; 31: 1521-1531.
106. 2004 Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus Arth Rheum 2004; 50:2858-68
107. 2004 A world without Vioxx: To COX-2 or not to COX-2. Cleveland Clinic J Med 2004: 71:849-55
108. 2003 Radiographic Data from recent randomized controlled trials in rheumatoid arthritis: what have we learned? Arth Rheum 2003: 48:21-34.
109. 2003 MCID/Low disease activity state workshop: summary, recommendations, and research agenda J Rheumatol 2003; 30: 1115-8
110. 2003 MCID/Low disease activity state workshop: low disease activity state in rheumatoid arthritis J Rheumatol 2003; 30: 1110-11
111. 2003 Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria J Rheumatol. 2003; 30:1648-54.
112. 2003 Adalimumab, a Fully Human Anti–TNF-a Monoclonal Antibody, and Concomitant Standard Antirheumatic Therapy for the Treatment of Rheumatoid Arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) J Rheumatol 2003: 30: 2563-71
113. 2003 . Repair of erosions in rheumatoid arthritis does occur. Results from 2 studies by the OMERACT Subcommittee on Healing of Erosions J Rheumatol. 2003; 30: 1102-7
114. 2003 An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the ACR 20% response criteria (ACR20) or the disease activity score (DAS) in a RA clinical Trial Arth Rheum 2003; 48: 625-30
115. 2003 The use of low dose glucocorticoid therapy in early rheumatoid arthritis Clin Exp Rheum 2003; 21: S186-190
116. 2003 Investigator Consortium and Crawford B: Improvement in health-related quality of life in SLE Patients Enrolled in a Randomized Clinical Trial Comparing LJP 394 Treatment with Placebo Lupus 2003; 12:677-86
117. 2003 LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double blind, placebo controlled study Arth Rheum 2003; 48: 442-54
118. 2002 How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion Arth Rheum 2002; 47: 215-8
119. 2002 Concomitant Leflunomide Therapy in Patients with Active Rheumatoid Arthritis despite Stable doses of Methotrexate Annals Int Med 2002; 137:726-33
120. 2002 Predictors and outcomes of scleroderma renal crisis: data from the high dose vs low dose D-penicillamine in early diffuse systemic sclerosis trial Arth Rheum 2002; 46:2836-7.
121. 2002 Using estimated yearly progression rates to compare radiographic data across recent randomized controlled trials in rheumatoid arthritis Ann Rheum Ds 2002; 61: ii64-ii66
122. 2002 Corticosteroid Sparing Efficacy of DHEA for female patients with mild to moderate systemic lupus erythematosus. Arth Rheum 2002; 46:1820-9
123. 2002 The effects of disease modifying anti-rheumatic drugs on the HAQ score. Lessons from the leflunomide clinical trials database. Rheumatology 2002; 41: 899-909
124. 2002 The Risk of Cardiovascular Thrombotic events with selective Cyclooxygenase-2 Inhibitors Arth Rheum 2002; 47:349-55.
125. 2002 Economic comparison of leflunomide and methotrexate in patients with active rheumatoid arthritis Pharmacoeconomics 2002; 20:61-70.
126. 2001 Minimum clinically important differences in plain films in RA J Rheum 2001; 28:914-7
127. 2001 Review: Monoclonal antibodies and other biologic therapies Lupus 2001; 10: 216-21
128. 2001 Leflunomide for rheumatoid arthritis: Defining its role J Musculoskeletal Med 2001; 18:277-84
129. 2001 Assessing efficacy measures for severe rheumatoid arthritis Pharm Therapeutics Supp; Mar 2001:3-7
130. 2001 Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity Index. J Rheum 2001; 28:1188-91
131. 2001 A proposal for developing a large patient population cohort for longterm safety monitoring in rheumatoid arthritis J Rheum 2001; 28:1170-3.
132. 2001 Towards a Common Understanding of Comparative Toxicity/Safety Profiles for Antirheumatic Therapies J Rheum 2001; 28:1163-69.
133. 2001 New therapies in development for autoimmune diseases: their rationale for combination treatment Sem Immunopathology 2001; 23:4-61
134. 2001 Two year treatment of active rheumatoid arthritis with leflunomide compared with methotrexate Arth Rheum 2001; 40:1984-92
135. 2001 Radiography of rheumatoid arthritis in the time of increasing drug effectiveness Curr Rheum Reports 2001; 3:46-52
136. 2001 Recent Rheumatoid Arthritis Clinical Trials Using Radiographic Endpoints – Updated research agenda J Rheum 2001; 28:887-9
137. 2000 Clinical Improvement as Reflected in Measures of Function and Health Related Quality of Life: Sensitivity and Relative Efficiency to Detect a Treatment Effect in a 12 month Placebo Controlled Trial Comparing Leflunomide with Methotrexate Arth Rheum 2000; 43:506-14
138. 2000 Biologic Agents in the treatment of rheumatoid arthritis Current Pharmaceutical Biotechnology 2000; 1:217-33
139. 2000 Recent developments for optimal end-points in rheumatoid arthritis clinical studies Ds Manage Health Outcomes 2000; 8:87-97
140. 2000 A proposal for developing a large patient population cohort for long-term safety monitoring in rheumatoid arthritis J Rheum 2000; 27:827-30
141. 2000 A meta-analysis of treatment termination rates in rheumatoid arthritis patients receiving disease modifying anti-rheumatic drugs Rheumatology 2000; 39: 975-81
142. 2000 Efficacy and safety in clinical trials for the treatment of rheumatoid arthritis. Drugs Today 2000; 36:383-94
143. 2000 Issues Involved in a Metaanalysis of RA Radiographic Progression J Rheum 2000; 27: 544-8
144. 2000 Endpoints: Consensus Recommendations from OMERACT IV Lupus 2000; 9:322-7
145. 2000 Treatment with Leflunomide Slows Radiographic Progression of RA – Results from 3 Randomized Controlled Trials of Leflunomide in Patients with Active Rheumatoid Arthritis Arth Rheum 2000; 43:495-505
146. 2000 Leflunomide, an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune disease Immunopharmacology 2000; 47:273-89
147. 1999 Treatment of Active Rheumatoid Arthritis with Leflunomide Compared to Placebo and Methotrexate. Archives Int Med 1999; 159:2542-50
148. 1999 Leflunomide for the treatment of rheumatoid arthritis Bull Rheum Ds 1999; 48:8
149. 1999 Imaging in Rheumatoid Arthritis: Results of Group Discussions J Rheum 1999; 26:749-51
150. 1999 Combination biologic therapy Clinical Exper Rheum 1999; 17:S21-4
151. 1999 Mechanism of Action for Leflunomide in Rheumatoid Arthritis. Clinical Immunology 1999; 93:198-208
152. 1999 Advances in the Treatment of Rheumatoid Arthritis Clinical Cornerstone 1999; 2:38-47
153. 1999 Biologic Agents and Innovative Interventional Approaches in the Management of SLE Curr Opin Rheum 1999; 11:330-40
154. 1999 Function and health related quality of life—results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis Arth Rheum 1999; 42:1870-8
155. 1999 Efficacy, Safety and Pharmacokinetics of the combination of methotrexate and leflunomide in patients with active rheumatoid arthritis Arth Rheum 1999; 42:1322-8
156. 1999 Randomized Clinical Trials and Longitudinal Observational Studies in SLE: Consensus on a Preliminary Core Set of Outcome Domains J Rheum 1999; 26: 504-7
157. 1999 Outcome Measures in Clinical Trials in Systemic Lupus Erythematosus J Rheum 1999; 26: 490-7
158. 1999 Steroid withdrawal favours joint erosion in rheumatoid arthritis Clin Exper Rheum 1999; 17:519-20
159. 1998 Use of the Interleukin-2 (IL-2) Fusion Protein DAB389 IL-2 for the Treatment of Psoriasis Dermatologic Therapy 1998; 5:48-63
160. 1998 T cell receptor peptide vaccination in rheumatoid arthritis: a placebo controlled trial using a combination of Vβ3, 14 and 17 peptides Arth Rheum 1998; 41:1919-29.
161. 1998 The OMERACT Filter for Outcome Measures in Rheumatology Editorial. J Rheum 1998; 25:198-9
162. 1998 A Survey of US and Canadian rheumatologists’ therapeutic choices in moderate and aggressive rheumatoid arthritis J Rheum 1998; 25:2331-8.
163. 1997 Biologic Agents and Innovative Interventional Approaches in the Management of SLE Curr Opin Rheum 1997; 9:410-20
164. 1997 Workshop Report: WHO/ILAR Taskforce on Quality of Life J Rheum 1997; 24: 1630-3.
165. 1997 Future use of biologic agents alone and in combination for the treatment of rheumatoid arthritis J Rheum 1997; 57:17-49
166. 1997 Meeting Report: Innovative Therapies in Autoimmune Diseases ID Research Alert, Weekly Highlights June 11, 1997:20-25.
167. 1997 Recommendations for a Core Set of Outcome Measures for Future Phase III Trials in Knee, Hip and Hand Osteoarthritis J Rheum 1997; 24:799-802
168. 1997 Clinical response to nonsteroidal antiinflammatory drugs Editorial. Arth Rheum 1997; 40: 1940-43
169. 1996 The Future Use of Biologic Agents in Combination for Treatment of Rheumatoid Arthritis J Rheum 1996; 23:91-6
170. 1996 Proceedings: Biologic Agents in Autoimmune Disease IV Conference Summary and Final Comments pp. 233-236
171. 1996 A Double Blind, Placebo Controlled Study of Anti-CD 5 Immunoconjugate in Patients with Rheumatoid Arthritis. Arth Rheum 1996; 39:1002-8
172. 1995 OMERACT II: The biologics perspective J Rheum 1995; 22:1415-7.
173. 1995 Safety and Effectiveness of Leflunomide in the Treatment of Patients with Active Rheumatoid Arthritis - Results of a Randomized Double Blind Placebo Controlled Phase II Trial Arth Rheum 1995; 38:1595-1603
174. 1995 Immunologic Assessment during Treatment of Rheumatoid Arthritis with Anti-CD5 Immunoconjugate J Rheum 1995; 22:207-13
175. 1995 American College of Rheumatology Preliminary Definition of Improvement in Rheumatoid Arthritis Arth Rheum 1995; 38:727-35.
176. 1994 A pilot study of anti CD5 Ricin A chain immunconjugate in Systemic Lupus Erythematosus. J Rheum 1994; 21:2068-70
177. 1994 Biologic Interventions in Rheumatoid Arthritis J Biotechnology in Health Care 1994-5; 1: 283-302 and 1: 377-95
178. 1994 Administration of an anti-CD5 immunoconjugate to patients with rheumatoid arthritis. Selective decrease in synovial collagenase gene expression Arth Rheum 1994; 37:193-200
179. 1994 Evaluating Biologic Agents in Rheumatoid Arthritis: A Framework for Clinical Trials. Editorial. J Rheum 1994; 21:1390-2.
180. 1994 Are There Special Considerations Relevant to Trials of Biologic Agents? J Rheum 1994; 21: 41-5
181. 1994 Treatment with an Anti-CD5 Immunoconjugate: Effect on Peripheral T cells and in vitro Assays of Immune Function in Patients with Rheumatoid Arthritis J Rheum 1994; 21:596-604
182. 1993 Effects of Administration of an Anti-CD5 Immunoconjugate in Rheumatoid Arthritis: Results of Two Phase II Studies Effects of Administration of an Anti-CD5 Immunoconjugate in Rheumatoid Arthritis: Results of Two Phase II Studies
183. 1993 OMERACT and the Clinical Evaluation of New Therapeutic Agents: A Bird's Eye View J Rheum 1993; 20:588-9
184. 1993 In Vivo T Cell Depletion in Rheumatoid Arthritis is Associated with Increased In Vitro IgM Rheumatoid Factor Synthesis Clin Immunol Immunopath 1993; 67:124-9.
185. 1993 Differential Patterns of Response to Treatment with an Anti-CD5 Immunoconjugate in Patients with Rheumatoid Arthritis Clin Exper Rheum 1993; 11:161-3.
186. 1992 The Emerging Role of Biologics in Rheumatic Diseases Perspectives in Pediatric Rheumatology". J Rheum 1992; 19: 40-5
187. 1991 Trial Design and Concepts Specific to Biologic Agents Proceedings: Early Decisions in DMARD Development II: Biologic Agents in Autoimmune Disease, Strand V. Ed. Amento E, Scribner C. Assoc Eds. Arthritis Foundation
188. 1991 Use of an Anti-CD5 Immunoconjugate in Rheumatoid Arthritis Proceedings: Early Decisions in DMARD Development II: Biologic Agents in Autoimmune Disease, Strand, V. Ed. Amento E, Scribner C. Assoc Eds. Arthritis Foundation
189. 1988 Ganciclovir Treatment of Life-or-Sight-Threatening Cytomegalovirus Infection: Experience in 314 Immuno-Compromised Patients Rev Infect Dis 1988; 10:S490-94
190. 1984 Non-Steroidal Anti-Inflammatory Drugs . Luke's Hospital Drug and Therapeutics Bulletin, Feb. 1984
191. 1983 Natural Killing Activity in Sjogren's Syndrome Arth Rheum 1983; 26:954-60
192. 1983 Adult Arthritis: Drugs and Remedies American Journal of Nursing 1983; 83:266-270
193. 1983 Lymphocyte Subsets in Sjogren's Syndrome: A Quantitative Analysis Using Monoclonal Antibodies and the Fluorescence-Activated Cell Sorter J Clin Lab Immunol 1983; 10:63-9
194. 1982 Antibody to Cytomegalovirus in Patients with Sjogren's Syndrome. Arth Rheum 1982; 25:260-5
195. 1981 Concomitant Renal and Hepatic Failure Treated by Polyacrylonitrile Membrane Hemodialysis. Inter J Artif Organs 1981; 3:136-9
196. 1980 Advances in the Diagnosis and Concept of Sjogren's Syndrome Bull Rheum Ds 1980; 30:1046-52
197. 1978 Essential Hypernatremia Am.J.Med.Sci 1978; 8:353-8
198. 1974 Plasminogen Activator and Alkaline Phosphatase in Guinea Pig Vessels Arch Path Lab Med 1974.
199. 1972 Fibrinolytic Activity in the Closed Ductus Arteriosus Experientia 1972; 28:448-9


Biotech China 2014
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.